PSMAddition Trial of Upfront Lutetium-177-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer - Andrew Armstrong
Related coverage: PSMAddition Trial of Upfront Lutetium-177-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer - Andrew Armstrong UroToday
Aug 12, 2026